The board of the pharmaceutical cash shell company said it had evaluated several potential reverse takeover candidates with major shareholders in the first quarter of 2018 but had concluded a potential takeover was not deemed to be practical.
Woodford is the largest shareholder, owning about 33% of the business. Abaco Capital makes up 0.05%, roughly £4m, of his £6.6bn flagship Equity Income fund. It is not held in his Income Focus fund or Patient Capital trust.
Abaco Capital, formerly known as Oxford Pharmascience Group (OPG), will seek shareholder approval for its proposed de-listing and liquidation at its annual general meeting on 8 May.
Following its demerger from its subsidiary Oxford Pharmascience Ltd (OPL) last December, which saw it …
Read the full article at: https://international-adviser.com/woodford-pharma-darling-proposes-de-listing-and-liquidation/
